Congress Materials – International Myeloma Society (IMS 2024)
2024 International Myeloma Society | Sep 25-28 | Rio de Janeiro, Brazil
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
A Discrete Choice Experiment Analysis to Understand Treatment Preferences of Patients With Relapsed or Refractory Multiple Myeloma (RRMM) in the United States
Beth Faiman, Hoa H. Le, Julie Laurent, Saurabh Petal, Agne Paner-Straseviciute, Xinke Zhang, Joseph Mikhael
Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functionally High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis
Surbhi Sidana, Katja Weisel, Luciano J. Costa, Niels W.C.J. van de Donk, Yaël C. Cohen, Duncan Purtill, Cyrille Touzeau, Carlos Fernández de Larrea, Joaquín Martínez-López, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, Man Zhao, Katherine Li, Martin Vogel, Mythili Koneru, Nitin Patel, Erika Florendo, Octavio Costa Filho, María-Victoria Mateos
Clinical Outcomes of Teclistamab Among MajesTEC-1 Eligible and Ineligible Population in the Real-World Setting for the Treatment of Relapsed/Refractory Multiple Myeloma
Carlyn Rose Tan, Andriy Derkach, Kylee Maclachlan, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Sridevi Rajeeve, Hamza Hashmi, Gunjan L. Shah, Michael Scordo, David J. Chung, Heather J. Landau, Sergio A. Giralt, Alexander Lesokhin, Neha Korde, Dee Lin, Bingcao Wu, Jessica Fowler, Mariana Fernandez, Nina Kim, Margaret Doyle, Laura Hester, Jennifer S. Orozco, Saad Z. Usmani
Comparative Efficacy of CARVYKTI in CARTITUDE-4 Versus Alternative Treatments From Daratumumab Clinical Trials for the Treatment of Patients With Lenalidomide-Refractory Multiple Myeloma
Michel Delforge, Irit Avivi, María-Victoria Mateos, Kristina Carlson, João Mendes, Seina Lee, Keqin Qi, Jordan M. Schecter, William Deraedt, Carolina Lonardi, Ana Slaughter, Diana Chen, Man Zhao, Kaitlyn Connors, Nitin Patel, Erika Florendo, Hermann Einsele, Binod Dhakal, Wilfried Roeloffzen
Comparative Efficacy of Cilta-Cel vs Approved Comparator Treatments for Patients With Relapsed/Refractory Multiple Myeloma With 1–3 Prior Lines of Therapy: A Network Meta-Analysis
Roberto Mina, Abdullah M. Khan, Brian McClune, Noffar Bar, Jo Caers, Jeremy Larsen, João Mendes, Seina Lee, Nina Benachour, Diana Chen, Man Zhao, Carolina Lonardi, Ana Slaughter, Tamar Lengil, Heather Burnett, Allie Cichewicz, Binod Neupane, Octavio Costa Filho, Dominik Dytfeld, Surbhi Sidana
Cytokine Release Syndrome in Patients Receiving Alternative Step-Up Doses of Talquetamab for Relapsed/Refractory Multiple Myeloma: Results From the Phase 1/2 MonumenTAL-1 Study
Daniel Morillo, Carmen Martinez Chamorro, María-Victoria Mateos, Luciano J. Costa, Monique C. Minnema, Larysa Sanchez, Brandi W. Hilder, Indrajeet Singh, Joy Gong, Bonnie W. Lau, Tom Renaud, Paula Rodríguez-Otero
Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) and DARA Maintenance in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): CASSIOPEIA Minimal Residual Disease (MRD) Update
Jill Corre, Laure Vincent, Philippe Moreau, Benjamin Hebraud, Cyrille Hulin, Marie C. Béné, Annemiek Broijl, Denis Caillot, Michel Delforge, Thomas Dejoie, Thierry Facon, Jérôme Lambert, Xavier Leleu, Margaret Macro, Aurore Perrot, Sonja Zweegman, Winnie Hua, Maria Krevvata, Veronique Vanquickelberghe, Alba Tuozzo, Melissa Rowe, Robin Carson, Soraya Wuilleme, Hervé Avet-Loiseau, Pieter Sonneveld, on behalf of IFM and HOVON
Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): PERSEUS Cytogenetic Risk Analysis
Meletios A. Dimopoulos, Pieter Sonneveld, Paula Rodriguez-Otero, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J. van de Donk, Eirini Katodritou, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Joan Bladé, Philippe Moreau, Mario Boccadoro
Daratumumab SC + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Saad Z. Usmani, Thierry Facon, Vania Hungria, Nizar J. Bahlis, Christopher P. Venner, Marc Braunstein, Ludek Pour, Josep Marti, Supratik Basu, Yael C. Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Wojciech Legiec, Meral Beksac, Angelo Maiolino, Weiping Liu, Jianping Wang, Maria Krevvata, Lorena Lopez-Masi, Jodi Carey, Melissa Rowe, Robin Carson, Sonja Zweegman
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Transplant-eligible Patients With Multiple Myeloma: A Pooled Analysis of Patients Aged ≥65 Years From Both PERSEUS and GRIFFIN Studies
Paula Rodriguez-Otero, Peter M. Voorhees, Mario Boccadoro, Jacob Laubach, Hermann Einsele, Douglas Sborov, Meletios A. Dimopoulos, Annemiek Broijl, Roberto Mina, Andrew Spencer, Fredrik Schjesvold, Rebecca Silbermann, Francesca Gay, Luciano Costa, Aurore Perrot, Yanfang Liu, Jianping Wang, Anna Sitthi-Amorn, Robin Carson, Annelore Cortoos, Saad Z. Usmani, Paul G. Richardson, Philippe Moreau, Pieter Sonneveld, Jonathan L. Kaufman
Diagnostic Challenges Across the Multiple Myeloma Pathway: Perspectives of Primary Care Physicians and Orthopedic Specialists
Faith E. Davies, Hayley Beer, Beth Faiman, J. Blake Bartlett, Georgia Attfield, Maya Gilbert, Daniel Egbase, Joseph Mikhael
Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Receiving CAR-T Therapy in the Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma
Sébastien Anguille, Xavier Leleu, Moshe Gatt, Lionel Karlin, Andrew Spencer, Shinsuke Iida, Tadao Ishida, Yi Lin, Chang-Ki Min, Seok Jin Kim, Ana Slaughter, Carolina Lonardi, Nina Benachour, Martin Vogel, Vicki Plaks, Katherine Li, Diana Chen, Quanlin Li, Tamar Lengil, Mythili Koneru, Nitin Patel, Octavio Costa Filho, Simon J. Harrison, Jesús San-Miguel, Hermann Einsele
Efficacy/Safety of Ciltacabtagene Autoleucel ± Lenalidomide Maintenance in Patients With Multiple Myeloma Who Had Suboptimal Response to Frontline Autologous Stem Cell Transplant: CARTITUDE-2 Cohort D
Sébastien Anguille, Xavier Leleu, Moshe Gatt, Lionel Karlin, Andrew Spencer, Shinsuke Iida, Tadao Ishida, Yi Lin, Chang-Ki Min, Seok Jin Kim, Ana Slaughter, Carolina Lonardi, Nina Benachour, Martin Vogel, Vicki Plaks, Katherine Li, Diana Chen, Quanlin Li, Tamar Lengil, Mythili Koneru, Nitin Patel, Octavio Costa Filho, Simon J. Harrison, Jesús San-Miguel, Hermann Einsele
Impact of COVID-19 on Outcomes With Teclistamab in the Phase 1/2 MajesTEC-1 Study in Patients With Relapsed/Refractory Multiple Myeloma
Yaël C. Cohen, Wilfried Roeloffzen, Tessa Kerre, Mounzer Agha, Michel Delforge, Ira Braunschweig, Nishi Shah, Shambavi Richard, Melissa Alsina, Hermann Einsele, Pankaj Mistry, Helen Varsos, Christina Corsale, Jordan M. Schecter, Kevin C. De Braganca, Yogesh Jethava, Qingxuan Song, Tamar Lengil, Mythili Koneru, Muhammad Akram, Bertrand Arnulf
Infections and Immune Reconstitution in the Phase 3 CARTITUDE-4 Trial of Ciltacabtagene Autoleucel vs Standard Care in Patients With Lenalidomide-Refractory Multiple Myeloma (MM) and 1–3 Prior Lines
Niels W.C.J. van de Donk, Joaquin Martínez-Lopez, Binod Dhakal, Magdalena Dutka, Leyla Shune, Cyrille Touzeau, Xavier Leleu, Yaël C. Cohen, Winfried Alsdorf, Roberto Mina, Katherine Li, Man Zhao, Quanlin Li, Arnab Ghosh, Martin Vogel, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, Vicki Plaks, Mythili Koneru, Nitin Patel, Erika Florendo, Albert Oriol, Rakesh Popat, P. Joy Ho
Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
Jing Christine Ye, Carolina Schinke, Cyrille Touzeau, Monique C. Minnema, Niels W.C.J. van de Donk, Paula Rodríguez-Otero, María-Victoria Mateos, Leo Rasche, Deeksha Vishwamitra, Indrajeet Singh, Xiang Qin, Michela Campagna, Tara Masterson, Brandi W. Hilder, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Colleen Kane, Ajai Chari
Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma
Rakesh Popat, Ajay K. Nooka, Niels W.C.J. van de Donk, Philippe Moreau, Manisha Bhutani, Albert Oriol, Thomas G. Martin, Laura Rosiñol, María-Victoria Mateos, Nizar J. Bahlis, Alfred L. Garfall, Britta Besemer, Joaquín Martínez-López, Amrita Y. Krishnan, Michel Delforge, Lin Huang, Deeksha Vishwamitra, Tara Stephenson, Katherine Chastain, Surbhi Sidana
Longer-Term Follow-Up of Patients Receiving Prophylactic Tocilizumab for Cytokine Release Syndrome in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma
Laura Rosiñol, Alfred L. Garfall, Lotfi Benboubker, Katarina Uttervall, Kaz Groen, Niels W.C.J. van de Donk, Jeffrey Matous, Deeksha Vishwamitra, Caroline Hodin, Tara Stephenson, Keqin Qi, Athena Zuppa, Katherine Chastain, María-Victoria Mateos
Overall Survival With Ciltacabtagene Autoleucel Versus Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Study Update
María-Victoria Mateos, Jesús San-Miguel, Binod Dhakal, Cyrille Touzeau, Xavier Leleu, Niels W.C.J. van de Donk, Surbhi Sidana, Albert Oriol, Yaël C. Cohen, Simon J. Harrison, Hermann Einsele, Paolo Corradini, Diana Chen, Quanlin Li, Katherine Li, Ana Slaughter, Carolina Lonardi, Nina Benachour, Martin Vogel, Nikoletta Lendvai, Mythili Koneru, Nitin Patel, Erika Florendo, P. Joy Ho, Rakesh Popat
Patient Preferences for Use of CAR-T Therapy as an Early Line Treatment in Multiple Myeloma
Doris K. Hansen, Jack Khouri, Omar Castaneda Puglianini, Kevin De Braganca, Denise De Wiest, Matthew Perciavalle, Tamar Lengil, Stephen Huo, Seina Lee, Kathryn Krupsky, Jesse Cohn, Elizabeth Brighton, Todd Bixby, Zaina P. Qureshi, Shambavi Richard
Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel vs Standard of Care in Patients With Lenalidomide-Refractory Multiple Myeloma After 1–3 Lines of Therapy
Katja Weisel, Roberto Mina, Anne K. Mylin, Hisayuki Yokoyama, Hila Magen, Winfried Alsdorf, Monique C. Minnema, Leyla Shune, Iris Isufi, Simon J. Harrison, Urvi A. Shah, Jordan M. Schecter, Nikoletta Lendvai, Katharine S. Gries, Eva G. Katz, Ana Slaughter, Carolina Lonardi, Jane Gilbert, Quanlin Li, William Deraedt, Octavio Costa Filho, Nitin Patel, Lionel Karlin
Perspectives of Single-Center Community Hematologists/Oncologists on Minimal Residual Disease Testing Among Patients With Multiple Myeloma
Lucio Gordan, Amanda Warner, Trevor Heritage, Amy Ming, Niodita Gupta-Werner, Shuchita Kaila, Annelore Cortoos
Prophylactic Interventions for Oral Toxicities With the GPRC5D×CD3 Bispecific Antibody Talquetamab in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase 2, Randomized Study (TALisman)
Rakesh Popat, Alexa Laheij, Niels W.C.J. van de Donk, Richard Doty, Jim Omel, Brea Lipe, Leo Rasche, Ajai Chari, Kelly Kato, Ken Tian, Deeksha Vishwamitra, Jacqueline Speier, Mathilde Durand, Margaret Northup, Ibrahim Saber, William Prada, Kathleen Gray, Gloria Aguilar, Larysa Sanchez
Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome in Patients Receiving Talquetamab for Relapsed/Refractory Multiple Myeloma: Results From the Phase 1/2 MonumenTAL-1 Study
Carolina Schinke, Ravi Vij, Sundar Jagannath, Larysa Sanchez, Matthew Pianko, Andrzej Jakubowiak, Tara J. Masterson, Michela Campagna, Guoqiang Zhang, Kathleen Gray, Thomas Renaud, Bonnie W. Lau, Gareth Morgan
Real-Life Outcomes in Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Carfilzomib- and/or Pomalidomide-Based Regimens in the LocoMMotion and MoMMent Studies
María-Victoria Mateos, Katja Weisel, Maria Esther Gonzalez Garcia, Hermann Einsele, Joanna Lindsey-Hill, Valerio De Stefano, Britta Besemer, Laure Vincent, Suriya Kirkpatrick, Lionel Karlin, Hartmut Goldschmidt, Concetta Conticello, Wilfried Roeloffzen, Niels W.C.J. van de Donk, Michel Delforge, Pamella Villanova, Margaret Doyle, Kathleen Gray, Claire Albrecht, Vadim Strulev, Jozefien Buyze, Jonathan Squire, Philippe Moreau
Real-World Data on the Use of Subcutaneous Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone in Transplant-eligible Patients With Newly Diagnosed Multiple Myeloma
Vania Hungria, Fernanda Lemos Moura, Paulo Soares, Juliana Souza Lima, Lisa Aquaroni Ricci, Fabio Moore Nucci, Eduardo Flávio Oliveira Ribeiro, Edvan de Queiroz Crusoe, Marinus de Moraes Lima, Roberto Jose Pessoa de Magalhães Filho, Celso Arrais-Rodrigues, Amitabha Bhaumik, Trilok Parekh, Fredrik Borgsten, Robin Carson, Damila C. Trufelli, Abel Costa Neto
Real-World Experience With Talquetamab Clinical Management in Relapsed Refractory Multiple Myeloma (RRMM): A Qualitative Study of US Healthcare Providers
Caroline Schinke, Hoa H. Le, Binod Dhakal, Sandra Mazzoni, Samantha Shenoy, Sara A. Scott, Tiffany Richards, Amalia DeBrosse, Peter Okorozo, Rachel McDowell, Saurabh Patel, Jonathan Bunn, Kelly Hawks, Xinke Zhang, Cesar Rodriguez
Stem Cell (SC) Yield and Transplant With Daratumumab ± Bortezomib, Lenalidomide and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma Patients in the Phase 3 PERSEUS Study
Pieter Sonneveld, Meletios A. Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Niels W.C.J. van de Donk, Yanfang Liu, Jianping Wang, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodriguez-Otero, Joan Bladé, Philippe Moreau
Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: Primary Results From the Phase 3 AURIGA Study
Ashraf Badros, Laahn Foster, Larry D. Anderson Jr., Chakra Chaulagain, Erin Pettijohn, Andrew J. Cowan, Caitlin Costello, Sarah Larson, Doug Sborov, Kenneth H. Shain, Rebecca Silbermann, Nina Shah, Alfred Chung, Maria Krevvata, Huiling Pei, Sharmila Patel, Vipin Khare, Annelore Cortoos, Robin Carson, Thomas S. Lin, Peter Voorhees
Talquetamab + Daratumumab + Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma: Results From the Phase 1b TRIMM‑2 Study
Nizar Bahlis, Niels W.C.J. van de Donk, Donna Reece, Manisha Bhutani, Bhagirathbhai Dholaria, Anita D’Souza, Thomas G. Martin, John McKay, Alfred Garfall, Amrita Krishnan, Kalpana Bakshi, Lijuan Kang, Lien Vandenberk, Thomas Prior, Jaszianne Tolbert, Ajai Chari
Talquetamab + Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Updated Phase 1b Results From RedirecTT-1 With >1 Year of Follow-Up
Yaël C. Cohen, Hila Magen, Moshe Gatt, Michael Sebag, Kihyun Kim, Chang-Ki Min, Enrique M. Ocio, Sung-Soo Yoon, Michael P. Chu, Paula Rodríguez-Otero, Irit Avivi, Natalia A. Quijano Cardé, Maria Krevvata, Michelle R. Peterson, Emma Scott, Brandi W. Hilder, Jill Vanak, Arnob Banerjee, Albert Oriol, Daniel Morillo, María-Victoria Mateos
Talquetamab Utilization Patterns and Dose Schedules in the United States: A Real-World Analysis
Rahul Banerjee, Ruibin Wang, Yi-Hsuan Liu, Jinghua He, Hoa Le, Saurabh Patel, Xinke Zhang
Talquetamab Versus Belgian Real-World Clinical Practice in Triple-Class Exposed Relapsed and Refractory Multiple Myeloma Patients Using Adjusted Comparison
Marie-Christiane Vekemans, Sébastien Anguille, Julien Depaus, Nathalie Meuleman, Ann Van de Velde, Isabelle Vande Broek, Francesca Ghilotti, Marco Trevisan, Jedelyn Cabrieto, Joris Diels, Oleksiy Orel, Ronald Brok, Sophie Vandervennet, Ann Smet, Susanne Lub, Michel Delforge
Talquetamab vs Real-World Physician’s Choice in Patients With Relapsed/Refractory Multiple Myeloma and Prior B-cell Maturation Antigen Therapy: Analyses of MonumenTAL-1 vs LocoMMotion/MoMMent
María-Victoria Mateos, Andrzej Jakubowiak, Hermann Einsele, Carolina Schinke, Britta Besemer, Sebastien Anguille, Salomon Manier, Leo Rasche, Hartmut Goldschmidt, Niels W.C.J. Van de Donk, Aurore Perrot, Raphael Teipel, Lionel Karlin, Christof Scheid, Jesus San Miguel, Charlotte Pawlyn, Joaquín Martinez-Lopez, Michele Cavo, Joris Diels, Thomas Renaud, Oleksiy Orel, Jedelyn Cabrieto, Nolen Perualila, Katja Weisel, Philippe Moreau
Treatment Positioning Model to Evaluate the Survival Benefit of Ciltacabtagene Autoleucel in Second Line Compared With Later Line Treatment of Lenalidomide-Refractory Multiple Myeloma
Rafael Fonseca, Eunju Todd, Sandhya Nair, João Mendes, Jianming He, Seina Lee, Thomas G. Martin
Trial in Progress (REALiTEC): A Retrospective Multi-Country Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With Teclistamab Outside of Clinical Trials
Aurore Perrot, Stéphanie Harel, K. Martin Kortüm, Katarina Uttervall, Bhuvan Kishore, Michele Cavo, Rana Takchi, Diptendu Santra, Claire Albrecht, Eva Rubio-Azpeitia, Rakesh Popat
Updated Comparative Effectiveness of Talquetamab vs Real-World Physician’s Choice of Treatment in LocoMMotion and MoMMent for Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Hermann Einsele, Philippe Moreau, Nizar Bahlis, Manisha Bhutani, Laure Vincent, Lionel Karlin, Aurore Perrot, Hartmut Goldschmidt, Niels W.C.J. van de Donk, Enrique M. Ocio, Joaquín Martínez López, Paula Rodríguez-Otero, Dominik Dytfeld, Joris Diels, Vadim Strulev, Imène Haddad, Thomas Renaud, Jedelyn Cabrieto, Nolen J. Perualila, Eric Ammann, Trilok Parekh, Claire Albrecht, Katja Weisel, María-Victoria Mateos
Updated Comparative Effectiveness of Talquetamab vs Real-World Physician’s Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Jing Christine Ye, Noa Biran, Sandhya Nair, Xiwu Lin, Keqin Qi, Eric Ammann, Thomas Renaud, Colleen Kane, Trilok Parekh, Kathleen Gray, Xinke Zhang, Luciano J. Costa
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.